Wave Life Sciences Ltd. Ordinary Shares - WVE STOCK NEWS

Wave Life Sciences (Nasdaq: WVE) announced significant advancements in its research regarding PN chemistry for stereopure oligonucleotides, highlighted by two publications in Nucleic Acids Research. The studies demonstrate that PN chemistry enhances potency, distribution, and durability in preclinical models for CNS and neuromuscular diseases. Wave's ongoing clinical programs target ALS, DMD, and Huntington’s disease. The first clinical data from PN chemistry-containing oligonucleotides is expected in 2022. The research emphasizes the importance of stereochemistry in therapeutic design.

Wave Life Sciences has partnered with the Alzheimer's Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD) to advance the FOCUS-C9 Phase 1b/2a clinical trial for WVE-004, targeting C9orf72-associated frontotemporal degeneration (C9-FTD) and amyotrophic lateral sclerosis (C9-ALS). This collaboration aims to evaluate various biomarkers for effective treatment assessments. WVE-004's novel oligonucleotide chemistry could significantly impact treatment outcomes in these neurodegenerative diseases.

Vintage Wine Estates (NASDAQ: VWE) has reached a significant milestone with its Angels Share campaign, donating over one million meals to combat food insecurity in the U.S. Since its inception eight years ago, the initiative has partnered with the Redwood Empire Food Bank and various other organizations across states like Colorado and Maryland. In a recent event, the company packed 3,000 food boxes for local distribution, continuing its commitment to support communities during challenging times.

Wave Life Sciences Ltd. (Nasdaq: WVE) announced its third-quarter 2021 financial results, reporting a net loss of $6.2 million, significantly down from $33.1 million in Q3 2020. Revenue surged to $36.4 million from $3.4 million, mainly due to a $22.5 million collaboration payment from Takeda. The company strengthened its balance sheet with $52 million in cash, focusing on RNA editing programs. Ongoing clinical trials are expected to yield data through 2022, with plans to announce its first ADAR editing candidate for alpha-1 antitrypsin deficiency next year.

Wave Life Sciences Ltd. (Nasdaq: WVE) announced that CEO Paul Bolno will participate in an analyst-led fireside chat during the Stifel 2021 Virtual Healthcare Conference on November 15, 2021, at 10:00 a.m. ET. A live webcast will be accessible through the Investor Relations page on the company's website. Wave Life Sciences focuses on developing genetic medicines for devastating diseases using its proprietary PRISM platform to design and produce stereopure oligonucleotides, aiming for groundbreaking therapeutic advancements.

Wave Life Sciences Ltd. (Nasdaq: WVE) announced a live webcast and conference call for its third quarter 2021 financial results, scheduled for November 10, 2021, at 8:30 a.m. ET. The event will provide important business updates and can be accessed via the company's Investor Relations website or by phone with the provided dial-in details. Wave Life Sciences is focused on developing genetic medicines through its proprietary PRISM platform, aiming to deliver innovative therapies for genetically defined diseases.

Wave Life Sciences Ltd. (Nasdaq: WVE) announced an amendment to its collaboration with Takeda Pharmaceutical, discontinuing the discovery component while maintaining options for late-stage CNS programs. Takeda will pay Wave $22.5 million for related expenses. This change enables Wave to advance CNS programs independently, excluding three specified targets. Ongoing clinical trials for WVE-004 and WVE-003 are unaffected. Wave's cash runway remains stable, expected to fund operations into Q2 2023, bolstering investor confidence in the company's strategic direction.

Wave Life Sciences has announced the initiation of a Phase 1b/2a clinical trial for WVE-N531, targeting Duchenne muscular dystrophy (DMD) in boys amenable to exon 53 skipping. This candidate is notable for utilizing a novel PN backbone chemistry. Preclinical data revealed a significant increase in dystrophin production and survival rates in animal models. The study aims to evaluate safety, pharmacokinetics, and pharmacodynamics in 15 participants aged 5 to 12 years. Clinical data from this trial is expected to inform future development decisions throughout 2022.

Wave Life Sciences (WVE) presented promising preclinical data on its ADAR-mediated RNA editing capabilities at the 2021 Analyst and Investor Research Webcast. Key highlights include:

• Editing levels in CNS tissues sustained for at least four months.
• Four-fold increase in serum AAT protein restoration over control, with 85% identified as functional M-AAT.
• Application in AAT deficiency treatment shows durable restoration of M-AAT protein.

These advancements demonstrate Wave's leadership in RNA editing, with ongoing studies to enhance therapeutic applications across multiple diseases.